These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8432504)

  • 1. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
    Stone AM; Greenstein RA; Gamble G; McLellan AT
    Hosp Community Psychiatry; 1993 Feb; 44(2):176-7. PubMed ID: 8432504
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
    Raskind M; Alvarez C; Herlin S
    J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol dependence and hospitalization in schizophrenia.
    Gerding LB; Labbate LA; Measom MO; Santos AB; Arana GW
    Schizophr Res; 1999 Jul; 38(1):71-5. PubMed ID: 10427612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
    Dhopesh V; Macfadden A; Maany I; Gamble G
    Psychiatr Serv; 1997 Jan; 48(1):95-7. PubMed ID: 9117510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.
    Stuyt EB; Sajbel TA; Allen MH
    Am J Addict; 2006; 15(2):166-73. PubMed ID: 16595355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
    Gaby N; Lefkowitz D; Israel JR
    N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
    [No Abstract]   [Full Text] [Related]  

  • 14. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia.
    Petrakis IL; Leslie D; Finney JW; Rosenheck R
    Am J Addict; 2006; 15(1):44-9. PubMed ID: 16449092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse.
    Kivlahan DR; Heiman JR; Wright RC; Mundt JW; Shupe JA
    Hosp Community Psychiatry; 1991 Jun; 42(6):609-14. PubMed ID: 1864571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse in schizophrenia: is there a relationship to substance abuse?
    Gupta S; Hendricks S; Kenkel AM; Bhatia SC; Haffke EA
    Schizophr Res; 1996 May; 20(1-2):153-6. PubMed ID: 8794503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.